PhageTech, Inc. is a Southern California company founded in 2014. PhageTech’s core technology was developed by two world-class researchers at the University of California, Irvine supported by a team of research scientists, postdoctoral researchers and graduate students. The collaboration between Dr. Reginald Penner and Dr. Gregory Weiss brought together two experts in analytical chemistry and molecular recognition.
The original core bioconducting technology was developed over ten years of intensive NIH-funded research, made possible through $2.2M in grants awarded to Dr. Penner and Dr. Weiss. PhageTech, Inc. evolved the technology to the CarePoint-Assay, an electrochemical point-of-care sandwich ELISA sensor system that will enable rapid and sensitive detection of disease biomarkers at their early stages.